Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
暂无分享,去创建一个
Travis J Cohoon | Kwok-Kin Wong | J. Qi | J. Bradner | T. Shimamura | J. Carretero | A. Kung | A. Kimmelman | M. Soucheray | Zhao Chen | E. Kikuchi | Esra A. Akbay | Alec C. Kimmelman | Yandi Gao | Katherine A. Cheng | J. Tchaicha | E. Akbay | Margaret Soucheray | Kwok-kin Wong | Travis J. Cohoon
[1] G. Evan,et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. , 2013, Genes & development.
[2] K. Stegmaier,et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.
[3] H. Varmus,et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.
[4] Charles Y. Lin,et al. Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.
[5] J. Bradner,et al. Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma , 2012, Clinical Cancer Research.
[6] Andrew L. Kung,et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.
[7] D. Bar-Sagi,et al. RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.
[8] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[9] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[10] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[11] M. Wilkerson,et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. , 2010, Cancer cell.
[12] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[13] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[14] Patricia Greninger,et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.
[15] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[16] Sridhar Ramaswamy,et al. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.
[17] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.
[18] G. Evan,et al. Modelling Myc inhibition as a cancer therapy , 2008, Nature.
[19] M. Meyerson,et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. , 2008, Cancer research.
[20] D. Neil Hayes,et al. LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.
[21] U. Weidle,et al. Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line , 2005, Oncogene.
[22] Joseph R. Nevins,et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.
[23] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[24] J. Darnell. Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.
[25] Stella Pelengaris,et al. c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.
[26] T. Jacks,et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.
[27] U. Weidle,et al. The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.
[28] Y Taya,et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.